Phase 2 randomized study evaluating safety, efficacy, and optimal dose of ABBV-400 in combination with fluorouracil, folinic acid, and bevacizumab in previously treated patients with metastatic colorectal cancer
Publication
, Conference
Raghav, KPS; Hubert, A; Fakih, M; Fang, H; Aristide, MRN; de Almeida, CB; Vasilopoulos, A; Sui, Y; Strickler, JH
Published in: JOURNAL OF CLINICAL ONCOLOGY
2024
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2024
Volume
42
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Raghav, K. P. S., Hubert, A., Fakih, M., Fang, H., Aristide, M. R. N., de Almeida, C. B., … Strickler, J. H. (2024). Phase 2 randomized study evaluating safety, efficacy, and optimal dose of ABBV-400 in combination with fluorouracil, folinic acid, and bevacizumab in previously treated patients with metastatic colorectal cancer. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 42).
Raghav, Kanwal Pratap Singh, Ayala Hubert, Marwan Fakih, Hua Fang, Martha Raluca Neagu Aristide, Carla Biesdorf de Almeida, Athanasios Vasilopoulos, Yunxia Sui, and John H. Strickler. “Phase 2 randomized study evaluating safety, efficacy, and optimal dose of ABBV-400 in combination with fluorouracil, folinic acid, and bevacizumab in previously treated patients with metastatic colorectal cancer.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 42, 2024.
Raghav KPS, Hubert A, Fakih M, Fang H, Aristide MRN, de Almeida CB, et al. Phase 2 randomized study evaluating safety, efficacy, and optimal dose of ABBV-400 in combination with fluorouracil, folinic acid, and bevacizumab in previously treated patients with metastatic colorectal cancer. In: JOURNAL OF CLINICAL ONCOLOGY. 2024.
Raghav, Kanwal Pratap Singh, et al. “Phase 2 randomized study evaluating safety, efficacy, and optimal dose of ABBV-400 in combination with fluorouracil, folinic acid, and bevacizumab in previously treated patients with metastatic colorectal cancer.” JOURNAL OF CLINICAL ONCOLOGY, vol. 42, no. 16, 2024.
Raghav KPS, Hubert A, Fakih M, Fang H, Aristide MRN, de Almeida CB, Vasilopoulos A, Sui Y, Strickler JH. Phase 2 randomized study evaluating safety, efficacy, and optimal dose of ABBV-400 in combination with fluorouracil, folinic acid, and bevacizumab in previously treated patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2024.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2024
Volume
42
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences